Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + MEDI4736 in Relapsed/Refractory Lymphomas
NCT02401048Phase 2Completed
- Sponsor
- Pharmacyclics
- Start
- May 2015
- Primary completion
- Nov 2017
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, durvalumab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Pharmacyclics. Started May 2015; status: completed.
02
Drugs
ibrutinibdurvalumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02401048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02401048.